Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients

Table 3

SpA patient’s characteristics when serum samples were collected.

Total SpA patients, (57.1%)
AS patients,
PsA patients,
Gender: male, (%)	58 (71.6)
Median age, years, mean ± SD	41.85 ± 11.23
Months of treatment, when blood samples were collected, median (IQR) (interval):
ADA	6 (3–18) (3–78)
ETA	30 (12–54) (6–72)
INF	54 (21–66) (3–108)
Number of performed tests, (%)
ADA	16 (19.8)
ETA	32 (39.5)
INF	33 (40.7)
Erosive disease, (%)	43 (53.1)
HLA-B27 positive, (%)	60 (74.1)
Sacroiliitis, (%)	64 (79.0)
TJC-60, median (IQR)	2 (0–4)
SJC-60, median (IQR)	1 (0–2)
Doctor’s GDA, mm, mean ± SD	22.45 ± 14.0
Patient’s GDA, mm, median (IQR)	21 (8.25–45.75)
DAS28, mean ± SD	2.37 ± 1.36^*
HAQ, median (IQR)	0.38 (0–0.88)
BASDAI, mm, median (IQR)	2.24 (1.02–4.66)^**
ASDAS-CRB, mean ± SD (interval)	4.77 ± 3.2
ESR, mm/h, median (IQR)	8 (4–21)
CRP, mg/L, median (IQR)	3.6 (1.05–7.58)
DMARDs use, (%)	66 (81.56)
MTX use, (%)	63 (77.8)
Medium MTX dose, mg/week, mean ± SD	10.93 ± 5.07
GK use, (%)	35 (43.2)
Prednisolone equivalent dose, mg/d, mean ± SD	8.07 ± 5.77

Notes: data presented mean ± standard deviation or median and interquartile range (IQR) or number () and percent of total number of patients; ^*peripheral forms of SpA, ^**axial form of SpA.
Abbreviations: SpA: spondyloarthritis, AS: ankylosing spondylitis, PsA: psoriatic arthritis, IQR: interquartile range; SD: standard deviation, TJC-60: 60 tender joint count, SJC-60: 60 swollen joint count, GDA: global disease activity visual analogue scale (0–100 mm), DAS28: disease activity score in 28 joints; HAQ: Health Assessment Questionnaire, BASDAI: Bath ankylosing spondylitis disease activity index (0–100 mm), ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DMARDs: disease-modifying antirheumatic drugs (e.g., methotrexate, sulfasalazine, leflunomide, hydrochloroquine, and azathioprine); MTX: methotrexate, and na: data is not applicable.